In this study, we developed four ADCs targeting epidermal growth factor receptor (EGFR), epidermal growth factor receptor 2 (Her2), trophoblast cell-surface antigen 2 (Trop2), and tissue factor (TF) that are highly expressed on ovarian cancer cells. This evidence concerns the gene ERBB2 and ovarian carcinoma.